阿帕替尼联合替吉奥治疗晚期胃癌的疗效观察  

Efficacy Observation of Apatinib plus S1 for the Treatment of Advanced Gastric Cancer

作　　者：马靓 赵霞[1] 钱琦 朱志远 陈平[1] MA Liang;ZHAO Xia;QIAN Qi;ZHU Zhiyuan;CHEN Ping(Department of Oncology, the Fourth Affiliated Hospital of Nantong University, Yancheng, Jiangsu, 224000, Chin)

机构地区：[1]南通大学第四附属医院肿瘤科,江苏盐城224000

出　　处：《肿瘤药学》2018年第2期174-178,共5页Anti-Tumor Pharmacy

基　　金：国家自然科学基金(30471702)

摘　　要：目的探讨阿帕替尼联合化疗治疗晚期胃癌的疗效、影响因素及安全性。方法本院收治的66例经二线及二线以上治疗失败的晚期胃癌患者,均经病理确诊。分别给予联合组:阿帕替尼+替吉奥(S1),靶向组:阿帕替尼,对照组:最佳支持治疗。2个月后复查影像学,按RECIST 1.1版标准评价客观疗效,同时随访其生存情况并比较不同临床特征的中位无进展生存期(PFS)和总生存期(OS)。结果所有患者均可评价疗效。阿帕替尼可提高晚期胃癌患者的疾病控制率(DCR),相较于单用阿帕替尼,联合化疗还能进一步提高胃癌患者的DCR(P<0.05)。对于AFP阳性的胃癌患者,阿帕替尼的疗效优于AFP阴性患者,且OS和PFS更长(P<0.05)。结论阿帕替尼联合S1治疗晚期胃癌仍有较好的疾病控制及生存获益,尤其是对AFP阳性患者的疗效更佳。Objective To evaluate the efficacy, safety and influence of apatinib combined s1 for the treatment of advanced gastric cancer patients. Methods 66 patients with advanced gastric cancer diagnosed by pathology were divided into three groups to receive chemotherapy combine targeted therapy （S1＋aptinib）, target treatment （aptinib）, and best supportive care. Response to therapy was assessed by RECIST criteria 1.1. The clinical follow-up data were investigated for comparison of median progression-free survival （PFS） and overall survival （OS） between different clinicopathologic characteristics. Results All patients were available for evaluation. DCR of advanced gastric cancer could be improved by apatinib. Furthermore, apatinib combined S1 could improve the DCR of paients compared with single apatinib （P〈0.05）. Efficacy of apatinib was better for AFP positive patients than for AFP negative patients （P〈0.05）. Conclusion Administration of apatinib combined with S1 in advanced gastric cancer patients was still beneficial in terms of higher disease control rate and better survival, espe-cially in AFP GC.

关 键 词：胃癌 阿帕替尼 替吉奥 化学治疗 靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤]